R&D Center Layout - The company utilizes a central research institute to coordinate and integrate regional R&D resources across four major centers [2] - The Kunming center focuses on traditional Chinese medicine and natural drug research [2] - The Beijing center collaborates with Peking University for academic and commercial research [2] - The Shanghai center develops innovative nuclear medicine products [2][3] - The Wuxi center specializes in medical device development for chronic disease treatment [3] Nuclear Medicine R&D System - Strong R&D capabilities with a rich reserve of leading talents, leveraging Peking University's resources for drug target discovery [4] - Integrated industrial chain capabilities through collaboration with top research institutions and strategic partnerships [4] - Proactive strategic layout in nuclear medicine, addressing unmet clinical needs in oncology and immunology [4] - Financial strength to support long-term R&D investments across all stages of drug development [5] Cloud Nuclear Medicine Overview - Cloud Nuclear Medicine was established in July 2023 in Tianjin, with a construction area of over 6,000 square meters [6] - Equipped with advanced facilities for drug screening, development, and clinical sample production [6] - Received radiation safety certification in October 2024, enabling the use of radioactive isotopes for drug development [6] INR101 Nuclear Medicine Project - INR101 is a Class 1 radioactive diagnostic drug for prostate cancer, initiated in September 2022 [7] - Clinical approval obtained in May 2024, with promising stability and safety results reported in November [7][8] - Phase III clinical trials commenced in May 2025, involving over 30 top GCP institutions [8] INR102 Nuclear Medicine Project - INR102 is a targeted radioactive ligand drug for prostate cancer, utilizing Lu-177 for precise delivery [9] - First-in-human clinical trials began in October 2024, with 12 patients enrolled showing good safety and efficacy [9][10] - Clinical trial approval received in April 2025, marking a new phase in the project [10][11]

Group 1: Pharmaceutical Business Performance - In 2024, the pharmaceutical segment achieved a revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [2] - The sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [2] - The sales of other traditional Chinese medicine products, such as Pudilan's anti-inflammatory tablets, reached nearly 200 million CNY, with a significant growth of over 22% [4] Group 2: Traditional Chinese Medicine Supply Chain Development - Yunnan Baiyao is committed to being the "chain leader" in the traditional Chinese medicine supply chain in Yunnan Province [3] - The company established a specialized traditional Chinese medicine seed company to control genetic resources [4] - The "Shuzhi Cloud Medicine" platform was launched, facilitating transactions exceeding 100 million CNY [4] Group 3: Oral Care Product Sales and Market Strategy - The health product segment generated 6.526 billion CNY in revenue, with a year-on-year growth of 1.6% [5] - Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - The company is enhancing its channel strategy by optimizing traditional offline channels and exploring new retail formats [5] Group 4: Q1 2025 Financial Performance - In Q1 2025, the company reported a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [7] - The net profit attributable to shareholders was 1.935 billion CNY, growing by 13.67% [7] - The cash flow from operating activities reached 714 million CNY, up 35.39% year-on-year [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024 and completed its I/IIa phase clinical summary report in November [8] - The company’s subsidiary received approval for the clinical trial of INR102, aimed at treating metastatic castration-resistant prostate cancer [9]